TNBC, a high Ki67 value, age under 49, and premenopausal status are predictive factors for a favorable response to PST. Additionally, TNBC and HER2+ cancers with intermediate TIL scores post-PST based on anthracyclines or CMF will have a favorable prognosis. This evidence concerns the gene ERBB2 and cancer.